Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Semaglutide

GLP-1 receptor agonist31 amino acidsBrand: Ozempic, Wegovy, Rybelsus

AFDA Approved
95
Excellent Credibility
3 cited studies | Evidence level A

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Mechanism of Action

Mimics endogenous GLP-1, binding to GLP-1 receptors in the pancreas, gut, and brain. Enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling.

Benefits

  • Mean 15% body weight loss in obesity trials (STEP 1)[1]
  • Significant HbA1c reduction in type 2 diabetes[2]
  • Reduced major cardiovascular events (SELECT trial)[3]
  • Available in oral formulation (Rybelsus)[2]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Semaglutide - Dosing in Published Research

Reported routes: Subcutaneous injection, Oral
Ozempic: titrated from 0.25 mg to 0.5-1 mg SC weekly. Wegovy: titrated to 2.4 mg SC weekly. Rybelsus: 3-14 mg oral daily.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting (especially during titration)[1]
  • Diarrhea or constipation[1]
  • Pancreatitis risk (rare)[1]
  • Gallbladder disorders[1]
  • Potential thyroid C-cell tumor risk (animal studies)[1]

Discuss Semaglutide with a doctor

Semaglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Get the Provider Checklist

Start with the evidence and provider checklist while routing is offline.

FDA approvedBoard-certified doctorsPrescription if appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Semaglutide in PeptideScholar's approved-treatment dataset

Semaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Ozempic, Wegovy, Rybelsus.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

Semaglutide Next Steps

NL selected - using US-first conversion assets
Treatment Hub
Semaglutide Treatment Guide

Approved product paths, real cost friction, provider routing, and tracker next steps — all in one source-backed hub.

Open treatment hub →

Research & Evidence

Compare Semaglutide With

References

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021. "Semaglutide 2.4 mg produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks in 1,961 adults" [PMID: 33567185]
  2. 2.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. N Engl J Med, 2016. "Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in type 2 diabetes patients" [PMID: 27633186]
  3. 3.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).. N Engl J Med, 2023. "Semaglutide reduced major adverse cardiovascular events by 20% vs placebo in adults with obesity and established CVD but no diabetes" [PMID: 37952131]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Semaglutide FAQ